Skip to content

Using Virtual Reality Before Transcranial Magnetic Stimulation for the Treatment of OCD

Using Virtual Reality Before Transcranial Magnetic Stimulation for the Treatment of OCD

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06442527
Acronym
VR-TMS
Enrollment
0
Registered
2024-06-04
Start date
2025-05-01
Completion date
2025-12-01
Last updated
2026-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder

Keywords

TMS, Transcranial Magnetic Stimulation, Virtual Reality, VR

Brief summary

This study will focus on the use of Virtual Reality (VR) technology in patients receiving treatment using Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)

Interventions

DEVICEVirtual Reality

Virtual reality gear and content will be used prior to TMS session as part of the provocation items

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants must be at least 18 years old * Patients must have been clinically evaluated by a Yale Interventional Psychiatry Service physician who has deemed them appropriate to receive TMS for the treatment of OCD * Ability and willingness, in the investigator's judgement, to comply with the study procedure and study requirements.

Exclusion criteria

* Hearing or visual impairment to the degree that would interfere with ability to see or hear VR content. * Difficulty in understanding spoken or written English * Pregnancy * History of seizure disorder * Unable to provide informed consent * Dementia or other cognitive disorder or intellectual disability that would impair the subject's ability to understand the study procedure (per investigator judgment) * Any implanted medical device, risk of interference with which by the VR device in the investigator's judgment can put patient at additional undue risk. * Any other medical or psychiatric comorbidity that the investigator judges would put the participant at additional undue risk due to study participation or would impair subject's ability to participate in the study. * Was previously enrolled/randomized into the study

Design outcomes

Primary

MeasureTime frameDescription
Tolerability of VR treatment by qualitative assessmentWithin 1 hour after each treatment sessionTolerability will be assessed by open-ended interview of the patient about their experience and any difficulty tolerating VR

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSina Nikayin, MD

Assistant Professor, Departement of Psychiatry, Yale University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 28, 2026